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Abstract: Previous investigations have shown that the
signal transducers and activators of transcription (STATs)
signaling pathway play an important role in the modulation
of apoptosis after ischemia and reperfusion. The mecha-
nism for this enhanced cardioprotection is unknown, but
we believe that alterations STATs may play a role.To inves-
tigate this hypothesis, we examined the effects of angioten-
sion II type 1 (AT1) and angiotension II type 2 (AT2)
receptor antagonist added to cardioplegia on the down-
stream response of different STATs, connected with
proinflammatory pathways (STAT2, STAT5) and prohy-
pertrophic and antiapoptotic pathways (STAT3). Isolated,
nonworking hearts (n = 3 per group) from neonatal rats
were perfused aerobically (4°C) for 20 min in the Langen-
dorff mode with the modified St. Thomas’ Hospital no. 2
(MSTH2) cardioplegic solution (Group 1), the MSTH2 car-
dioplegic solution + AT1 receptor antagonist (Group 2),
and MSTH2 cardioplegic solution + AT2 receptor antago-
nist (Group 3). Thus, myocytes were isolated by enzymatic
digestion, and STAT2, STAT3, and STAT5 were investi-
gated in Western blot studies. Times to arrest after car-
dioplegia were 8–12 s for all groups. Total cardioplegia
delivery volume was about 300 mL for the 20 min. Perfu-
sion with the MSTH2 cardioplegic solution supplemented
with AT1 receptor antagonist (Group 2) induced a signifi-
cant reduction in STAT2 and STAT5 tyrosine phosphory-
lation (-58 and -63%, respectively, vs. Group 1, P < 0.05).
Conversely, STAT2 and STAT5 activation were unaffected
by perfusion with the MSTH2 cardioplegic solution supple-
mented with AT2 receptor antagonist (Group 3). The
decreased activation of STAT2 and STAT5 observed in
Group 2 was accompanied by reduction of interleukin-1b
(-57% in Group 2 vs. Group 1, P < 0.05). There were no
significant differences in STAT3 phosphorylation among all
groups. Only the addition of AT1 receptor antagonist to
MSTH2 cardioplegia significantly decreases the inflamma-
tory response of the neonatal rat cardiomyocytes without
affecting antiapoptotic influence provided by tyrosine
phosphorylation of STAT3.AT1 receptor antagonist added
to cardioplegia represents an additional modality for
enhancing myocardial protection during cardiac surgery
and could contribute to optimize the ischemia tolerance
of the pediatric heart. Key Words: Rat myocardium—
Cardioplegia—Angiotensin II antagonist—Valsartan—
Signal transducers and activators of transcription.
Although the tolerance of immature myocardium
to ischemia is greater than that of mature myocar-
dium, inadequate protection by crystalloid cardiople-
gia(s) for immature myocardium has been cited as
one of the major reasons for postoperative complica-
tions and deaths in children (1).
The interpretation of studies of cardioplegic effi-
cacy in the immature myocardium is complicated
by the variety of animal species, the range of
different cardioplegic solutions used, and different
hypothermias. Therefore, a considerable controversy
surrounds the ability of cardioplegic solutions to
protect the immature myocardium (2).
Absolutely high potassium (K+) cardioplegia has
been identified as a major factor associated with poor
outcomes in pediatric congenital, adult revascu-
larization, or valvular corrective operations (3).
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K+-induced depolarization and the resulting intracel-
lular sodium (Na+) and calcium (Ca2+) loading can
lead to myocardial and microvascular injury, coro-
nary vasoconstriction and spasm (4), arrhythmias (5),
and right and left ventricular stunning (6), and poten-
tiate the local inflammatory response with free
radical production (7) (excepting from electrochemi-
cal arrest, hyperkalemic cardioplegia offers the
patient little or no cardioprotection).
Moreover, the inflammatory reaction to cardiopul-
monary bypass and surgical trauma involves activa-
tion of leukocytes and endothelium, with secretion of
cytokines that contribute to the systemic inflamma-
tory response syndrome, multiple organ failure, and
postoperative myocardial motion abnormalities that
are frequently observed after cardiac surgery (8).
To minimize cell injury through oxidative stress, it
is necessary to either reduce production of oxygen
radicals, scavenge oxygen radicals effectively, or
block the conversion of reactive species of low reac-
tivity (e.g., hydrogen peroxide) to species of high
reactivity (e.g., hydroxyl radicals).
A direct link was found among angiotensin II, reac-
tive oxygen species (ROS) generation, glucose, and
the transmission of death signaling in rat myocytes
(p38 mitogen-activated protein kinase) (9). Previous
studies have shown that the signal transducers and
activators of transcription (STATs) signaling path-
ways activated by angiotensin II play an important
role in the modulation of apoptosis after ischemia
and reperfusion.
To investigate the hypothesis according to selective
angiotensin II antagonism can regulate STATs acti-
vation during cardioplegia, we examined the effects
of STATs modulation after infusion of modified St.
Thomas’ Hospital no. 2 (MSTH2) cardioplegia with
addition of angiotensin II type 1 (AT1) and type 2
(AT2) receptor antagonist, in particular related
with prohypertrophic and antiapoptotic pathways
(STAT3) and with proinflammatory pathways
(STAT2, STAT5).
MATERIALS AND METHODS
Animals
Neonatal Wistar rats (1–2 weeks) were fed ad
libitum and housed in a 14/10-h light/dark cycle. Rats
were anesthetized with an intraperitoneal injection
of thiopentone sodium (100 mg/kg body weight), and
hearts were rapidly excised. Rats were handled in
compliance with Verona University Ethics approval
and with the “Guide for care and use of laboratory
animals” from the National Institutes of Health.
Chemicals were obtained from Sigma-Aldrich Italia
(Milan, Italy).
Langendorff perfusion system
The chest was opened by a median sternotomy, and
the heart was rapidly excised and placed in ice-cold
perfusion medium. The time taken from opening the
chest to excision of the heart was 1–2 min. Immedi-
ately after, the aorta was connected to a standard
Langendorff apparatus and perfused with arresting
solutions in anterograde fashion at 80 cm H2O
(60 mm Hg). After infusion, hearts were switched
rapidly to nonworking mode, and cardioplegia was
managed for a total of 20 min at controlled tempera-
ture of 4°C (Checktemp Thermometer, LSS,
Janesville, WI, USA). Arresting solutions were
continuously oxygenated before and during
administration.
Arresting solutions
MSTH2 cardioplegia
MSTH2 is a sterile, nonpyrogenic, essentially iso-
tonic, formulation of electrolytes in water for
injection. It is a core solution intended for use only
after addition of sodium bicarbonate to adjust pH
prior to administration. After buffering with sodium
bicarbonate, it is suitable for cardiac instillation
(usually with hypothermia) to induce arrest during
open heart surgery.
Each 100 mL of solution contains calcium chloride
dihydrate 17.6 mg, magnesium chloride hexahydrate
325.3 mg, KCl 119.3 mg, and NaCl 643 mg in water
for injection. It may contain HCl or NaOH for pH
adjustment. Electrolyte content per liter (not includ-
ing ions for pH adjustment): Ca++ 2.4 mEq; magne-
sium (Mg++) 32 mEq; K+ 16 mEq; Na+ 110 mEq;
chloride (Cl-) 160 mEq. Osmolar concentration,
304 mOsmol/L (calc.); pH 3.8 (3.5 to 3.9) prior to
sodium bicarbonate (NaHCO3) addition.
It is required that 10 mL (840 mg) of 8.4%
NaHCO3 injection (10 mEq each of sodium and
bicarbonate) be added aseptically and thoroughly
mixed with each 1000 mL of cardioplegic solution to
adjust pH.Ten mL 8.4% of NaHCO3 injection should
be used to achieve the approximate pH of 7.8 when
measured at room temperature. Use of any other
NaHCO3 injection may not achieve this pH due to
the varying pHs of NaHCO3 injections. Due to its
inherent instability with other components, NaHCO3
must be supplemented just prior to administration.
After this addition, the solution must be stored under
refrigeration and be used within 24 h.
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The buffered admixture contains the following
electrolytes (per liter): Ca++ 2.4 mEq, Mg++ 32 mEq,
K+ 16 mEq, Na+ 120 mEq, Cl- 160 mEq, and HCO3-
10 mEq; osmolar concentration, 324 mOsmol/L
(calc.); pH 7.8 (approx.). If other agents are added,
these values may be altered.
MSTH2 cardioplegia plus AT1 and AT2 receptor
antagonists
To investigate the STATs modulation as conse-
quence of the relative role of the two AT receptor
subtypes, selective AT1 (Valsartan, 1 mmol/L) and
AT2 (PD123319, 1 mmol/L) receptor antagonists
were added to MSTH2 cardioplegia prior to
instillation. Ultimate solutions were indicated as
MSTH2 cardioplegia + AT1 and MSTH2 cardio-
plegia + AT2, respectively.
Infusion protocol
Neonatal rats were randomly assigned to three dif-
ferent groups. Group 1 was perfused with MSTH2 for
20 min at 4°C, in anterograde fashion at 80 cm H2O
(60 mm Hg) in the Langendorff perfusion system.
The time range of 20 min was chosen to exceed the
usual maximum storage time of human hearts, thus
creating stiff testing conditions. Group 2 and Group 3
were perfused in the same way with MSTH2
cardioplegia + AT1 and MSTH2 cardioplegia + AT2
solutions, respectively.
Rat heart isolation
Myocytes were isolated with the enzymatic diges-
tion method as previously described (10–13).
Briefly, the aorta previously cannulated for car-
dioplegia administration was perfused for 10 min at
37° with a calcium-free basic buffer (blood washout)
composed of Joklik modified minimal essential
medium (MEM Joklik) supplemented with
glutamine (0.3 g/L), taurine (1.25 g/L), N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid
(2.9 mmol/L), insulin (20 U/L), penicillin-
streptomycin (50 U/mL and 0.05 mg/mL, respec-
tively) 5 mL/L, and CaCl2 (7.5 mmol/L), pH 7.4. The
basic buffer was previously passed through filters of
0.2-mm pore size. Perfusion was then switched to
collagenase solution, composed of 0.5 mg/mL of col-
lagenase type II (100 units/mL) in basic buffer
supplemented with CaCl2 30 mmol/L (20 mL/min for
20–25 min).The collagenase-perfused tissue was then
minced, and tissue was collected in tubes containing
basic buffer supplemented with bovine serum
albumin (0.5%), CaCl2 (0.3 mmol/L), and taurine
(10 mmol/L). Individual myocytes were then released
from the tissue by mechanical agitation.
The suspension was filtered through sterile gauze
to separate cells from tissue mass. The populations of
cells were then washed using two complete cycles of
low-speed centrifugation. The dispersed cells were
finally preplated for 30 min to minimize fibroblast
contamination. Typical preparations contained
60–70% rod-shaped, quiescent Ca2+-tolerant myo-
cytes that had well-defined, regular cross-striations
and sarcomere patterns. According to their appear-
ance under phase contrast microscopy and by immu-
nocytochemical staining, nonmyocyte cells were
found to account for less than 2% of the total cells
(13–15).
Samples were washed in ice-cold phosphate-
buffered saline and lysed in ice-cold lysis buffer
(50 mmol/L Tris–HCl, 150 mmol/L NaCl, 1 mmol/L
sodium orthovanadate, 100 mmol/L NaF, 2 mmol/L
ethylene glycol tetraacetic acid. 1% NP40 (Tergitol
Solution, Sigma-Aldrich Italia), 1 mmol/L phenylm-
ethylsulfonyl fluoride (pH 7.4) supplemented with
Protease Inhibitor Cocktail and Phosphatase Inhibi-
tor Cocktail. Lysates were kept on ice, sonicated four
times for 5 s, and centrifuged at 13 000 ¥ g for 10 min.
After centrifugation, protein concentration in the
supernatant fraction was assessed by Bradford’s
method.
Western blotting studies
Samples (25 mg proteins) were then separated
with 8% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis.The gel was then transferred to nitro-
cellulose membrane (Hybond-ECL, Amersham Bio-
sciences, Piscataway, NJ, USA) and blocked by
incubation for 1 h at room temperature in Tris Tween
buffered saline (TTBS, pH 7.4) and 5% skimmed
milk powder. Membranes were then incubated over-
night at 4°C with polyclonal rabbit anti-mouse
STAT2 (Santa Cruz Biotechnology), polyclonal
rabbit anti-mouse phospho-STAT2 (Tyr690) (Cell
Signaling Technology, Danvers, MA, USA), poly-
clonal rabbit anti-mouse STAT3, polyclonal rabbit
anti-mouse phospho-STAT3 (Tyr705) (Cell Signaling
Technology), polyclonal rabbit anti-mouse STAT5
and polyclonal rabbit anti-mouse phospho-STAT5
(Tyr694) (Cell Signaling Technology), and polyclonal
rabbit anti-mouse interleukin (IL)-1b (Cell Signaling
Technology). The nitrocellulose membranes were
then washed twice for 10 min with TTBS and incu-
bated for 30 min with goat anti-rabbit or sheep anti-
mouse secondary antibodies labeled with horseradish
peroxidase. After extensive washing, the specific
bound antibody was visualized using a chemilumines-
cent detection system (ECL detection reagents,
Amersham Bioscience). The amount of each band
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was quantified using a densitometer software
(Quantity One, Bio-Rad, Hercules, CA, USA)
and normalized using the total protein amount
of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
Statistical analysis
Data are expressed as mean standard deviation.
Comparisons between groups were performed using
one-way analysis of variance and Student’s t-test, fol-
lowed by the Tukey–Kramer method, as appropriate.
A value of P < 0.05 was considered statistically
significant.
RESULTS
Times to arrest after cardioplegia were 8–12 s for
all three groups. Total cardioplegia delivery volume
was about 300 mL for the 20 min.
Western blot analyses performed on myocytes iso-
lated after infusion according to the protocol’s
scheme showed that AT1 receptor antagonist signifi-
cantly reduced STAT2 Tyr690 phosphorylation
(-58% in Group 2 vs. Group 1, P < 0.05) (Fig. 1) and
STAT5 Tyr694 phosphorylation (-63% in Group 2 vs.
Group 1, P < 0.05) (Fig. 1). Conversely, no change in
Tyr705 phosphorylation of STAT3 was observed (Fig.
1). The decreased activation of STAT2 and STAT5
activation in Group 2 was accompanied by consider-
able reduction of IL-1b (-57% in Group 2 vs. Group
1, P < 0.05) (Fig. 2). STAT2 and STAT5 activation
was blunted by AT1 receptor antagonism but not
AT2, as STAT2 Tyr690 phosphorylation only
increased 6% in Group 3 versus Group 1 (P = NS)
(Fig. 1) and STAT5 Tyr694 phosphorylation docu-
mented decreased 3% in Group 3 versus Group 1
(P = NS).
Therefore, STAT2 and STAT5 responses were
all mediated by AT1 receptor subtype, as indicated
by the relative effects of Valsartan rather than
PD123319 (1 mmol/L for both). Conversely, Tyr705
phosphorylation of STAT3 was unaffected by perfu-
sion with cardioplegia in the presence of AT1 or AT2
receptor antagonists (Fig. 1).
DISCUSSION
The effects of formulation and the physicochemi-
cal characteristics of cardioplegic solutions on myo-
cardial protection are substantial.The responsiveness
of age-related changes of hearts to ischemia and crys-
talloid cardioplegias also greatly affect the protection
effect.
The results of recent studies have demonstrated
that crystalloid cardioplegias can indeed confer sat-
isfactory protection on a model of immature rabbit
hearts subjected to hypothermic ischemic arrest at
14°C. However, the extent of protection and, hence,
the postischemic recovery of function, is highly
dependent on the composition of the solution used.
Experimental reports have shown that cardiople-
gic solutions used at St. Thomas’ Hospital and
Hopital Lariboisiere provided excellent protection
during hypothermic ischemic arrest in neonatal
rabbit hearts and resulted in functional recovery
superior to that achieved with hypothermia alone or
with the high potassium cardioplegic solution (16).
Thus, Ledingham et al. have determined the St.
Thomas’ Hospital solution 2 provides better protec-
tion than solution 1; to the best of our knowledge, no
clinical evidence has demonstrated superiority of St
Thomas’ solution 2 over solution 1, and their use is
still associated with significant reperfusion injury
(14).
FIG. 1. pSTAT2, pSTAT5, and pSTAT3 expression in myocytes
isolated from neonatal rat heart after perfusion with modified St.
Thomas Hospital no. 2 (MSTH2) cardioplegia (Group 1), MSTH2
cardioplegia supplemented with AT1 receptor antagonist (Group
2), and with MSTH2 supplemented with AT2 receptor antagonist
(Group 3). (A) Representative protein bands of pSTAT2, pSTAT5,
pSTAT3, and GAPDH detected by Western blotting. (B) The bar
graphs showing the densitometric analysis of the ratio of phos-
phorylated STAT (pSTAT2, pSTAT5, pSTAT3) to total GAPDH.
Data are the results of three experiments for each group of
myocytes. *P < 0.05 vs. Group 1.
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Although St. Thomas’ Hospital or Tyers solutions
confer excellent protection on the immature myocar-
dium, other crystalloid solutions as the Bretschneider
and Roe solutions are ineffective.
These results always derived from immature rabbit
hearts were different from the results of crystalloid
cardioplegias on adult hearts. The reasons underlying
these differences in cardioplegic efficacy probably
include age-related changes in cardiac metabolism,
and the way in which components of these solutions
interact with the ischemic myocardium. Consider-
ations about the changes among different solutions,
and between adult and immature hearts with the
same solution, may reveal features of the immature
myocardium that could be exploited in the design of
protective interventions.
In previous dose–response studies, protection in
the adult myocardium was shown to be highly depen-
dent on both the calcium and magnesium content of
the St. Thomas’ Hospital solution. The comparable
protection seen in the present studies with the St.
Thomas’ Hospital and other crystalloid solutions
might, therefore, suggest that the neonatal heart has a
different responsiveness to these ions than the adult
heart (15,17).
The mechanisms for neonatal cardioprotection are
not completely elucidated and partially unknown, but
we believe that alterations in STATs signal mediated
by changes in electrolytes balance may play a role
(18–20).
To further investigate this hypothesis, we have
examined the effects of selective AT1 and AT2 recep-
tor antagonist on tyrosine phosphorylation of
STAT2, STAT5, and STAT3.
Previous studies have shown that tyrosine phos-
phorylation of STATs is essential for dimerization
and translocation into the nucleus to allow for DNA
binding (2). STAT1, STAT2, and STAT5 tyrosine
phosphorylation has been shown to be associated
with the modulation of apoptosis.
Increased STAT2 tyrosine phosphorylation and
STAT1 has been associated with proapoptotic
responses in adult rat and human myocardium. Pre-
ceding findings have revealed that STAT1-deficient
mice develop spontaneous and chemically induced
tumors more rapidly than wild-type mice, and that
STAT1-deficient cells are more resistant to agents
that induce apoptosis (21). It has also been disclosed
that STAT1 and STAT2 modulate cardiac myocyte
apoptosis after simulated ischemia and reperfusion
(22). In contrast, depletion of STAT3 has been shown
to abolish the cardioprotection afforded by precon-
ditioning (23).
Our data reveal that STAT2 and STAT5 tyrosine
phosphorylation are significantly increased during
ischemia in Group 1 as compared with Group 2 (Fig.
1). The mechanism for this can be explained by the
downstream of proapoptotic response of STAT2 and
STAT5 operated by AT1 receptor antagonist without
affecting significantly antiapoptotic STAT3 tyrosine
phosphorylation, as evident in Group 1. These data
suggest that apoptosis may be the result of a shifting
of the balance between proapoptotic and antiapop-
totic levels.
We speculate that ischemia induces a growth in
proinflammatory STAT2 and STAT5 levels that
increases apoptosis. Antiapoptotic STAT3 levels are
not significantly decreased among the three groups.
This differential leads to a shift in balance toward the
reduction of apoptosis by STAT2 and STAT5.
Inhibition of AT2 receptors does not reflect on
downstream of proinflammatory STATs, although
AT2 receptors have been demonstrated in fetuses
(24). We can suppose an AT2 receptor downregula-
tion after birth in the cardiovascular system, but
other works need to sustain that hypothesis.
Previous reports have speculated that even the
preservation of mitochondrial structure and function
by diazoxide added to cardioplegia plays an impor-
tant role in the modulation of ischemia/reperfusion
injury (25). The mechanism through which the
FIG. 2. IL-1b expression in myocytes isolated from neonatal rat
heart after perfusion with modified St. Thomas Hospital no. 2
(MSTH2) cardioplegia (Group 1), MSTH2 cardioplegia supple-
mented with AT1 receptor antagonist (Group 2), and with MSTH2
supplemented with AT2 receptor antagonist (Group 3). (A) Rep-
resentative protein bands of IL-1b detected by Western blotting.
(B) The bar graph showing the densitometric analysis of the ratio
of IL-1b to total GAPDH. Data are the results of three experi-
ments for each group of myocytes. *P < 0.05 vs. Group 1.
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opening of mitochondrial ATP-sensitive K+ channels
with diazoxide significantly increases antiapoptotic
STAT3 tyrosine phosphorylation levels and DNA
binding remains to be fully elucidated.Yoo et al. have
shown that c-Jun interacts with STAT3 and enhances
STAT3 DNA binding (26).
STATs stimulation reveals on activation of proin-
flammatory cytokines that play an emerging role as
responsible factors for initiating and maintaining
myocardial response to environmental stress. The
short-term expression of cytokines seems to let the
myocardium rapidly react to injury and to activate
protective homeostatic responses to damage.
However, most recent experimental studies docu-
mented the negative immediate inotropic effect on
heart function, mainly in case of high levels of tumor
necrosis factor, IL-1, IL-2, and IL-6 (27).
In particular, IL-1a and IL-1b are synthesized as
31- to 34-kDa promolecules. They are released from
monocytes and macrophages as proteolytically pro-
cessed 17-kDa mature molecules that bind with high
affinity to specific receptors on target cells. IL-1 is
not released via the classic secretory pathway. The
promolecules are synthesized as cytosolic proteins
without signal peptides.
Hogquist et al. demonstrated that release of IL-1 is
efficiently induced by cell injury (28). When the
injury causes cellular necrosis, IL-1a is released as a
mixture of unprocessed and processed molecules, but
IL-1b is released exclusively as the biologically inac-
tive proform. In contrast, when cells undergo apop-
tosis, maturation of both IL-1a and IL-1b is efficient.
When apoptosis is rapid, as in macrophages that are
targets for allospecific cytotoxic T lymphocytes, pro-
cessing is observed to occur intracellularly. These
findings proposed that cell injury is an important
physiologic stimulus for release of IL-1, and nature of
the injury profoundly affects the forms of IL-1 that
are released.
Furthermore, elevated levels of IL-1 are found
after myocardial infarction and are considered to
play a major role in tissue remodeling events
throughout the heart (29).
The implication of proinflammatory cytokines in
cardiac surgery and the relationship to inflammatory
reaction due to cardiopulmonary bypass, myocardial
arrest, and surgical trauma have been also demon-
strated (30).
We first speculated the effects of the AT receptor
antagonism in relationship with a specific crystalloid
cardioplegia on myocardial stress in the experimental
neonatal rat model. The significant decrease of IL-1
level controlled by AT1 receptor antagonism should
have the effect of a decrease in myocardial cell
ischemic insult due to oxygen-derived free radi-
cals (ROS) local production even in neonatal
myocardium.
Myocardial cytokine reduction should be related
to protective effects against inflammatory response
mediated by proinflammatory STATs activation, with
probably less activation of complement leukocytes
and endothelial cells, and decreased generation of
ROS by polymorphonuclear neutrophils.
Additionally, infusion of moderate hypothermic
cardioplegia results in protection against apoptosis.
The role of hypothermia in the prevention of apo-
ptosis has been previously reviewed, and it has been
shown that mild hypothermia is somewhat protec-
tive, while deep hypothermia increases apoptosis
(31). In our model, we administer cold 4°C
cardioplegia. No attempt at modulation of tempera-
ture beyond these limits has been performed. We
have assumed from literature that deep hypothermia
may decrease transcription, and thus decrease the
antiapoptotic effects of STATs modulation; however,
further studies are needed to support this hypothesis.
CONCLUSION
Our data indicate that STAT2 and STAT5 tyrosine
phosphorylation are associated with increased apop-
tosis as confirmed by monitoring of IL-1b trend. Only
the addition of AT1 receptor antagonist at cardiople-
gia modulates apoptosis by significantly decreasing
tyrosine phosphorylation of STAT2 and STAT5
without significantly affecting STAT3 response. It
represents an additional modality for enhancing neo-
natal myocardial protection above all for patients at
greater risk to suffer from free radical injury when
they undergo surgical repair (e.g. tetralogy of Fallot).
Our work also raises an interest that the AT2
receptor antagonism does not modulate signaling
pathways mediated by STATs in neonatal rat
myocardium.
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